BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wuputra K, Ku CC, Wu DC, Lin YC, Saito S, Yokoyama KK. Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. J Exp Clin Cancer Res 2020;39:100. [PMID: 32493501 DOI: 10.1186/s13046-020-01584-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Duff C, Baruteau J. Modelling urea cycle disorders using iPSCs. NPJ Regen Med 2022;7:56. [PMID: 36163209 DOI: 10.1038/s41536-022-00252-5] [Reference Citation Analysis]
2 Shamsian A, Sahebnasagh R, Norouzy A, Hussein SH, Ghahremani MH, Azizi Z. Cancer cells as a new source of induced pluripotent stem cells. Stem Cell Res Ther 2022;13:459. [PMID: 36064437 DOI: 10.1186/s13287-022-03145-y] [Reference Citation Analysis]
3 Kim A, Lee S, Chung S. Caffeic acid selectively eliminates teratogenic human-induced pluripotent stem cells via apoptotic cell death. Phytomedicine 2022;102:154144. [DOI: 10.1016/j.phymed.2022.154144] [Reference Citation Analysis]
4 Heaton ES, Jin S. Importance of Multiple Endocrine Cell Types in Islet Organoids for Type 1 Diabetes Treatment. Transl Res 2022:S1931-5244(22)00148-7. [PMID: 35772687 DOI: 10.1016/j.trsl.2022.06.014] [Reference Citation Analysis]
5 Saito S, Ku C, Wuputra K, Pan J, Lin C, Lin Y, Wu D, Yokoyama KK. Biomarkers of Cancer Stem Cells for Experimental Research and Clinical Application. JPM 2022;12:715. [DOI: 10.3390/jpm12050715] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ho J, Yue D, Cheema U, Hsia HC, Dardik A. Innovations in Stem Cell Therapy for Diabetic Wound Healing. Adv Wound Care (New Rochelle) 2022. [PMID: 35176896 DOI: 10.1089/wound.2021.0104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Park J, Lee DG, Lee NG, Kwon M, Son YS, Son M, Bae K, Lee J, Park J, Lee N, Min J. Monoclonal antibody K312-based depletion of pluripotent cells from differentiated stem cell progeny prevents teratoma formation. BMB Rep 2022;55:142-7. [DOI: 10.5483/bmbrep.2022.55.3.090] [Reference Citation Analysis]
8 Brown SV, Dewitt S, Clayton A, Waddington RJ. Identifying the Efficacy of Extracellular Vesicles in Osteogenic Differentiation: An EV-Lution in Regenerative Medicine. Front Dent Med 2022;3:849724. [DOI: 10.3389/fdmed.2022.849724] [Reference Citation Analysis]
9 Zakharova I, Saaya S, Shevchenko A, Stupnikova A, Zhiven' M, Laktionov P, Stepanova A, Romashchenko A, Yanshole L, Chernonosov A, Volkov A, Kizilova E, Zavjalov E, Chernyavsky A, Romanov A, Karpenko A, Zakian S. Mitomycin-Treated Endothelial and Smooth Muscle Cells Suitable for Safe Tissue Engineering Approaches. Front Bioeng Biotechnol 2022;10:772981. [DOI: 10.3389/fbioe.2022.772981] [Reference Citation Analysis]
10 Patel SA. Functional genomic approaches in acute myeloid leukemia: Insights into disease models and the therapeutic potential of reprogramming. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215579] [Reference Citation Analysis]
11 Hwang JJ, Choi J, Rim YA, Nam Y, Ju JH. Application of Induced Pluripotent Stem Cells for Disease Modeling and 3D Model Construction: Focus on Osteoarthritis. Cells 2021;10:3032. [PMID: 34831254 DOI: 10.3390/cells10113032] [Reference Citation Analysis]
12 Fregona V, Bayet M, Gerby B. Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells. Cancers (Basel) 2021;13:5511. [PMID: 34771671 DOI: 10.3390/cancers13215511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Szustak M, Gendaszewska-Darmach E. Nanocellulose-Based Scaffolds for Chondrogenic Differentiation and Expansion. Front Bioeng Biotechnol 2021;9:736213. [PMID: 34485266 DOI: 10.3389/fbioe.2021.736213] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
14 Wuputra K, Ku CC, Kato K, Wu DC, Saito S, Yokoyama KK. Translational models of 3-D organoids and cancer stem cells in gastric cancer research. Stem Cell Res Ther 2021;12:492. [PMID: 34488885 DOI: 10.1186/s13287-021-02521-4] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Meyran D, Terry R, Zhu JJ, Haber M, Ziegler DS, Ekert P, Trapani JA, Darcy PK, Neeson PJ. Early-phenotype CAR-T cells for the treatment of pediatric cancers. Ann Oncol 2021:S0923-7534(21)02506-0. [PMID: 34375680 DOI: 10.1016/j.annonc.2021.07.018] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
16 Chour T, Tian L, Lau E, Thomas D, Itzhaki I, Malak O, Zhang JZ, Qin X, Wardak M, Liu Y, Chandy M, Black KE, Lam MP, Neofytou E, Wu JC. Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies. JCI Insight 2021;6:142000. [PMID: 33830086 DOI: 10.1172/jci.insight.142000] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
17 Bosch BM, Salero E, Núñez-Toldrà R, Sabater AL, Gil FJ, Perez RA. Discovering the Potential of Dental Pulp Stem Cells for Corneal Endothelial Cell Production: A Proof of Concept. Front Bioeng Biotechnol 2021;9:617724. [PMID: 33585434 DOI: 10.3389/fbioe.2021.617724] [Cited by in F6Publishing: 5] [Reference Citation Analysis]